Innate Pharma Presents Promising Preclinical Data for IPH6501 at EHA Congress

Innate Pharma SA ( (FR:IPH) ) just unveiled an update.

Innate Pharma announced the presentation of preclinical data for IPH6501, a novel NK cell engager targeting CD20, at the 2025 European Hematology Association Congress. The data demonstrated potent antitumor activity in diffuse large B-cell lymphoma and follicular lymphoma, particularly when combined with R-CHOP, the standard of care. These findings suggest IPH6501’s potential to improve treatment outcomes for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, supporting further clinical development.

The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK cell engagers, along with developing Antibody Drug Conjugates and monoclonal antibodies. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.

Average Trading Volume: 107,388

Technical Sentiment Signal: Strong Sell

Current Market Cap: €161.5M

See more insights into IPH stock on TipRanks’ Stock Analysis page.